Top Boehringer Ingelheim drug gets FDA approval in rare skin disease
For many patients with generalized pustular psoriasis (GPP), the journey to diagnosis could take years, as doctors can mistake the incredibly rare skin condition for an infection. And when they do get diagnosed, there are only a few drugs — none officially approved — they can use to manage the painful flares that characterize the disease.
Boehringer Ingelheim just got the green light to change that for US patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
